These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32301258)

  • 21. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications.
    Jordan S; Cunningham-Rundles C; McEwan R
    Am J Transplant; 2003 Jun; 3(6):653-64. PubMed ID: 12780556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience.
    Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M
    Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Pooled Immunoglobulin as Treatment of Active Antibody-Mediated Rejection of Transplanted Kidney.
    Furmańczyk-Zawiska A; Urbanowicz A; Perkowska-Ptasińska A; Bączkowska T; Sadowska A; Nazarewski S; Chmura A; Durlik M
    Transplant Proc; 2016 Jun; 48(5):1446-50. PubMed ID: 27496425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.
    Koslik MA; Friebus-Kardash J; Heinemann FM; Kribben A; Bräsen JH; Eisenberger U
    Front Med (Lausanne); 2022; 9():816555. PubMed ID: 35174191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates.
    Nair V; Sawinski D; Akalin E; Friedlander R; Ebcioglu Z; Sehgal V; Dinavahi R; Khaim R; Ames S; Lerner S; Murphy B; Bromberg JS; Heeger PS; Schröppel B
    Clin Transplant; 2012; 26(3):E261-8. PubMed ID: 22686949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
    Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA
    Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
    Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J
    Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.
    Matignon M; Pilon C; Commereuc M; Grondin C; Leibler C; Kofman T; Audard V; Cohen J; Canoui-Poitrine F; Grimbert P
    PLoS One; 2017; 12(6):e0178572. PubMed ID: 28654684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.
    Jordan SC; Toyoda M; Vo AA
    Expert Rev Clin Immunol; 2011 May; 7(3):341-8. PubMed ID: 21595600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient.
    Al-Uzri AY; Seltz B; Yorgin PD; Spier CM; Andreoni K
    Pediatr Transplant; 2002 Apr; 6(2):161-5. PubMed ID: 12000474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open label clinical trial of complement inhibition in multifocal motor neuropathy.
    Fitzpatrick AM; Mann CA; Barry S; Brennan K; Overell JR; Willison HJ
    J Peripher Nerv Syst; 2011 Jun; 16(2):84-91. PubMed ID: 21692905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients.
    Luke PP; Scantlebury VP; Jordan ML; Vivas CA; Hakala TR; Jain A; Somani A; Fedorek S; Randhawa P; Shapiro R
    Transplantation; 2001 Aug; 72(3):419-22. PubMed ID: 11502969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.
    Ravindranath MH
    J Immunol Res; 2017; 2017():3475926. PubMed ID: 28634589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
    Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
    Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.